PyroGenesis Canada (NASDAQ:PYRGF – Get Free Report) and Zymeworks (NASDAQ:ZYME – Get Free Report) are both small-cap industrials companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.
Profitability
This table compares PyroGenesis Canada and Zymeworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PyroGenesis Canada | -115.14% | N/A | -60.81% |
| Zymeworks | -126.92% | -37.97% | -25.31% |
Institutional and Insider Ownership
0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PyroGenesis Canada | 0 | 0 | 0 | 0 | 0.00 |
| Zymeworks | 1 | 1 | 7 | 2 | 2.91 |
Zymeworks has a consensus price target of $38.00, suggesting a potential upside of 54.85%. Given Zymeworks’ stronger consensus rating and higher possible upside, analysts plainly believe Zymeworks is more favorable than PyroGenesis Canada.
Volatility and Risk
PyroGenesis Canada has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
Earnings and Valuation
This table compares PyroGenesis Canada and Zymeworks”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PyroGenesis Canada | $9.14 million | 4.64 | -$21.12 million | ($0.04) | -5.13 |
| Zymeworks | $81.26 million | 22.05 | -$81.13 million | ($1.37) | -17.91 |
PyroGenesis Canada has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.
Summary
Zymeworks beats PyroGenesis Canada on 9 of the 15 factors compared between the two stocks.
About PyroGenesis Canada
PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.
About Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Receive News & Ratings for PyroGenesis Canada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PyroGenesis Canada and related companies with MarketBeat.com's FREE daily email newsletter.
